In this paper, a knittle pressure sensor was designed and fabricated by coating graphene/Polyvinylidene Fluoride nanocomposite on the knitted polyester substrate. The coating was carried out by a dip-coating method in a nanocomposite solution. The microstructure, surface properties and electrical properties of coated layers were investigated. The sensors were tested under the application of different pressures, and the corresponding sensor signals were analyzed in terms of resistance change. It was observed that the change in resistance was 55% kPa with a sensitivity limit of 0.25 kPa. The sensor model was created and simulated using COMSOL Multiphysics software, and the model data were favorably compared with the experimental results. This investigation suggests that graphene-based nanocomposites can be used in knittle pressure sensor applications.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672550 | PMC |
| http://dx.doi.org/10.3390/ma16227087 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Knittle Pressure Sensor Based on Graphene/Polyvinylidene Fluoride Nanocomposite Coated on Polyester Fabric.
Materials (Basel)
November 2023
Materials & Surface Engineering Research Institute, Kanto Gakuin University, Yokohama 236-0037, Japan.
In this paper, a knittle pressure sensor was designed and fabricated by coating graphene/Polyvinylidene Fluoride nanocomposite on the knitted polyester substrate. The coating was carried out by a dip-coating method in a nanocomposite solution. The microstructure, surface properties and electrical properties of coated layers were investigated.
View Article and Find Full Text PDFOutcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II.
Crit Care Med
June 2018
The University of Melbourne, Melbourne, VIC, Australia Austin Hospital, Heidelberg, VIC, Australia Department of Intensive Care, Royal Melbourne Hospital, Melbourne, VIC, Australia.
Objective: Acute kidney injury requiring renal replacement therapy in severe vasodilatory shock is associated with an unfavorable prognosis. Angiotensin II treatment may help these patients by potentially restoring renal function without decreasing intrarenal oxygenation. We analyzed the impact of angiotensin II on the outcomes of acute kidney injury requiring renal replacement therapy.
View Article and Find Full Text PDFAngiotensin II for the Treatment of Vasodilatory Shock.
N Engl J Med
August 2017
From Anesthesiology Institute, Center for Critical Care and Department of Outcomes Research, Cleveland Clinic, Cleveland (A.K.); the Department of Medicine (Critical Care), University of Ottawa, and the Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa (S.W.E.); Division of Critical Care Medicine, Department of Anesthesiology, Duke University Medical Center, Durham, NC (X.S.W.); Regions Hospital, St. Paul, MN (K.H.); University of Tennessee College of Medicine, Chattanooga (J.T.); the Division of Nephrology, Baylor University Medical Center, Dallas (H.S.); the Department of Medicine, Emory University School of Medicine, Atlanta (L.W.B.); Inova Medical Center, Falls Church, VA (L.A.); the Department of Internal Medicine, University of California Davis School of Medicine, Sacramento (T.E.A.), the Division of Critical Care, Department of Anesthesiology, University of California Los Angeles, Los Angeles (D.W.B.), and La Jolla Pharmaceutical Company, San Diego (J.J., S.K., L.S.C., G.F.T.) - all in California; the Department of Pulmonary and Critical Care Medicine, Riverside Methodist Hospital, Columbus, OH (C.M.); the Division of Pulmonary and Critical Care Medicine, University of Maryland School of Medicine, Baltimore (M.T.M.); the Department of Surgery, Sunrise Hospital, Las Vegas (S.C.); Intensive Care Unit, Wellington Hospital, and Medical Research Institute of New Zealand, Wellington, New Zealand (P.J.Y.); the Division of Critical Care, Department of Medicine, Eastern Idaho Regional Medical Center, Idaho Falls (K.K.); the Department of Medicine, Pulmonary and Critical Care, Northwestern University Feinberg School of Medicine, Chicago (R.G.W.); the Department of Critical Care and Nephrology, King's College London, Guy's and St. Thomas' Hospital, London (M.O.); the Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh (R.M.); the Department of Medicine, Albert Einstein College of Medicine, and the Division of Critical Care Medicine, Montefiore Medical Center, Bronx, NY (M.N.G.); John Hunter Hospital, New Lambton Heights, and School of Medicine and Public Health, University of Newcastle, Callaghan, NSW (R.P.), the Department of Intensive Care, Wesley Hospital and Princess Alexandra Hospital, University of Queensland, St Lucia (B.V.), and School of Medicine, University of Melbourne, Parkville (R.B.), and the Intensive Care Unit, the Royal Melbourne Hospital, University of Melbourne (A.M.D.), Melbourne, VIC - all in Australia; the Division of Intensive Care Medicine, Department of Anesthesiology, Intensive Care, and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki (J.H.); INSERM UMR 995 LIRIC (Lille Inflammation Research Center), Centre Hospitalier Universitaire Lille, Critical Care Center and University of Lille School of Medicine, Lille, France (R.F.); and the Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Harvard Medical School, Boston (B.T.T.).
Background: Vasodilatory shock that does not respond to high-dose vasopressors is associated with high mortality. We investigated the effectiveness of angiotensin II for the treatment of patients with this condition.
Methods: We randomly assigned patients with vasodilatory shock who were receiving more than 0.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!